Trials / Completed
CompletedNCT06668324
Multiple Sclerosis Patient Experience on Kesimpta and Ocrevus Subcutaneous Formulation
Multiple Sclerosis Patient Experience on Kesimpta and Ocrevus Subcutaneous Formulation (MS-PEKOS)
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 134 (actual)
- Sponsor
- Novartis Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years – 99 Years
- Healthy volunteers
- Not accepted
Summary
The study aims to compare the experiences, including injection-related reactions (IRRs) of patients newly receiving ofatumumab to those starting to receive ocrelizumab SC formulation
Conditions
Timeline
- Start date
- 2024-11-15
- Primary completion
- 2025-09-05
- Completion
- 2025-09-05
- First posted
- 2024-10-31
- Last updated
- 2025-09-19
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT06668324. Inclusion in this directory is not an endorsement.